ImmunoCellular Therapeutics and PharmaCell partner for trial in Europe
ICT-107 is a dendritic cell-based vaccine designed to prevent glioblastoma multiforme, one of the most common and deadly types of brain cancer. According to the agreed partnership, PharmCell will conduct a Technology Transfer for its contract manufacturing partner based in the U.S. The company will set up in Geleen, the Netherlands for the study.
"We are pleased to engage with PharmaCell, who have a proven ability to support companies in establishing a robust manufacturing capability in Europe in line with the strict standards of the regulatory authorities for Phase III and early stage commercial manufacturing for ATMPs (Advanced Therapy Medicinal Products),” ImmunoCellular CEO Andrew Gengos said.
PharmaCell CEO Alexander Vos said he welcomes the alliance.
“Their decision confirms that our new Geleen facility is indeed viewed by industry experts as meeting the requirements and client expectations for late clinical stage and commercial manufacturing for ATMPs," Voss said. "We look forward to support ImmunoCellular in their effort to develop ICT-107 for the benefit of European patients."